On ECHEMI
Home > Drugs > Cerebral atrophy
Cerebral atrophy
Brain atrophy refers to a type of neuropsychiatric disease caused by organic lesions in the brain tissue itself due to various reasons, resulting in atrophy. Brain atrophy includes pediatric brain atrophy and adult brain atrophy. It is more common in the elderly. This disease occurs in adults: it mostly occurs in people over 50 years old, the course of the disease can be several years to decades, and it is more common in men than in women. Brain atrophy includes diffuse brain atrophy (including cortical atrophy, cerebellar atrophy, and atrophy of the cortex, cerebellum, and brainstem) and localized brain atrophy (more common after localized brain organic lesions such as trauma, vascular disease, and localized intracranial infection).
  • Site of disease:

    Brain
  • Infectious :

    Not contagious
  • Frequent population:

    All groups
  • Related symptoms:

    Memory impairment intelligence decline fatigue easy to fall dizziness
Related Drugs
Monosialotetrahexosylganglioside sodium injection
Indication: Central nervous system diseases include cerebrospinal cord trauma, cerebrovascular accident, and Parkinson's disease.
Manufacturer:

Harbin Medical University Pharmaceutical Co., Ltd.

Guanxinkang Capsules
Manufacturer:

XI`AN Datown Pharmaceutical Group Co., Ltd.

Guanxinkang Capsules
Manufacturer:

Guangdong Taiantang Pharmaceutical Co., Ltd.

Monosialotetrahexosylganglioside sodium injection
Indication: Used to treat vascular or traumatic central nervous system injury; spinal cord injury; cerebral atrophy, cerebral infarction, cerebral hemorrhage, brain injury, cerebral palsy in children, neonatal hypoxic-ischemic encephalopathy, pediatric peripheral neuritis, Parkinson's disease, diabetic cranial neuropathy; diabetic peripheral neuropathy; peripheral neuropathy.
Manufacturer:

Changchun Xiangtong Pharmaceutical Co., Ltd.

Monosialotetrahexosylganglioside sodium injection
Indication: Used to treat vascular or traumatic central nervous system injury; spinal cord injury; cerebral atrophy, cerebral infarction, cerebral hemorrhage, brain injury, cerebral palsy in children, neonatal hypoxic-ischemic encephalopathy, pediatric peripheral neuritis, Parkinson's disease, diabetic cranial neuropathy; diabetic peripheral neuropathy; peripheral neuropathy.
Monosialotetrahexosylganglioside sodium injection
Indication: Used to treat vascular or traumatic central nervous system injury; spinal cord injury; cerebral atrophy, cerebral infarction, cerebral hemorrhage, brain injury, cerebral palsy in children, neonatal hypoxic-ischemic encephalopathy, pediatric peripheral neuritis, Parkinson's disease, diabetic cranial neuropathy; diabetic peripheral neuropathy; peripheral neuropathy.
Manufacturer:

Harbin Medical University Pharmaceutical Co., Ltd.

Monosialotetrahexosylganglioside sodium injection
Indication: For the treatment of vascular or traumatic central nervous system damage, Parkinson's disease
Monosialotetrahexosylganglioside sodium injection
Indication: Vascular or traumatic central nervous system injury; Parkinson's disease.
Manufacturer:

Qilu Pharmaceutical Co., Ltd.

Monosialotetrahexosylganglioside sodium injection
Indication: Vascular or traumatic central nervous system injury; Parkinson's disease.
Manufacturer:

Qilu Pharmaceutical Co., Ltd.

  • 1
  • 2
  • Go to Page Go
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.